CoChat

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease

Open access
Jin, Lee‐Way, Lucente, Jacopo Di, Nguyen, Hai M., Singh, Vikrant, Singh, Latika, Chavez, Monique, Bushong, Trevor, Wulff, Heike, Maezawa, Izumi · 2019 · Annals of Clinical and Translational Neurology
Cited by 72

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+‐activated potassium channel KC a3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KC a3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with A β oligomer (A β O) activated KC a3.1 in microglia, and if microglial KC a3.1 was upregulated in 5x FAD mice and in human AD brains. The expression/activity of KC a3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole‐cell patch‐clamp. To investigate the role of KC a3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KC a3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, A β deposition and hippocampal long‐term potentiation (hLTP) in 5x FAD mice. Results: We found markedly enhanced microglial KC a3.1 expression/activity in brains of both 5x FAD mice and AD patients. In hippocampal slices, microglial KC a3.1 expression/activity was increased by A β O treatment, and its inhibition diminished the proinflammatory and hLTP‐impairing activities of A β O. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5x FAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well‐tolerated in a prior phase‐3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.754

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Jin, L., Lucente, J. D., Nguyen, H. M., Singh, V., Singh, L., Chavez, M., Bushong, T., Wulff, H., & Maezawa, I.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2019-03-18
Volume
6
Issue
4
Pages
723-738
ISSN
2328-9503 (ISSN-L)
OpenAlex
W2922646819
Cited by
72
References
16
FWCI
5.00
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.